Recently, a change in the leadership of the IDIBAPS “Diagnosis and therapeutics in oncology” research group was approved. David Fuster will lead the group, replacing Francesca Pons, who is retiring. The group will also change its name to Multimodal Imaging Biomarkers and joins the Interdisciplinary Research Groups Area.
David Fuster started working at IDIBAPS in 2009 as a researcher. His research has focused on diagnostic imaging techniques, in particular positron emission tomography/computed tomography (PET/CT), and the assessment of response to treatment in digestive system tumours and in the field of cardiovascular infections. He is also co-author of the European Association of Nuclear Medicine guidelines for best clinical practice in Nuclear Medicine and, since 2018, has been the head of the Nuclear Medicine Service at the Hospital Clínic.
